Home Healthcare Biotechnology Biosimilar Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others), By Indication (Oncology, Autoimmune diseases, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Biosimilar Monoclonal Antibodies Market, By Type  2022-2034 (USD MILLION/ Units)
    1. Adalimumab
    2. Bevacizumab
    3. Infliximab
    4. Rituximab
    5. Trastuzumab
    6. Others
  2. Biosimilar Monoclonal Antibodies Market, By Indication  2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Autoimmune diseases
    3. Others
  3. Biosimilar Monoclonal Antibodies Market, By Distribution Channel  2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacies
    2. Drug Stores & Retail Pharmacies
    3. Others
  4. Regional Biosimilar Monoclonal Antibodies Market
    1. North America
      1. North America Biosimilar Monoclonal Antibodies Market By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      2. North America Biosimilar Monoclonal Antibodies Market By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      3. North America Biosimilar Monoclonal Antibodies Market By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      4. U.S.
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      5. Canada
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
    2. Europe
      1. Europe Biosimilar Monoclonal Antibodies Market By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      2. Europe Biosimilar Monoclonal Antibodies Market By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      3. Europe Biosimilar Monoclonal Antibodies Market By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      4. U.K.
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      5. Germany
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      6. France
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      7. Spain
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      8. Italy
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      9. Russia
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      10. Nordic
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      11. Benelux
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      12. Rest of Europe
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
    3. APAC
      1. APAC Biosimilar Monoclonal Antibodies Market By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      2. APAC Biosimilar Monoclonal Antibodies Market By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      3. APAC Biosimilar Monoclonal Antibodies Market By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      4. China
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      5. Korea
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      6. Japan
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      7. India
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      8. Australia
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      9. Taiwan
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      10. South East Asia
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      11. Rest of Asia-Pacific
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa Biosimilar Monoclonal Antibodies Market By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      2. Middle East and Africa Biosimilar Monoclonal Antibodies Market By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      3. Middle East and Africa Biosimilar Monoclonal Antibodies Market By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      4. UAE
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      5. Turkey
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      6. Saudi Arabia
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      7. South Africa
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      8. Egypt
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      9. Nigeria
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      10. Rest of MEA
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
    5. LATAM
      1. LATAM Biosimilar Monoclonal Antibodies Market By Type  2022-2034 (USD MILLION/ Units)
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
      2. LATAM Biosimilar Monoclonal Antibodies Market By Indication  2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Autoimmune diseases
        3. Others
      3. LATAM Biosimilar Monoclonal Antibodies Market By Distribution Channel  2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Drug Stores & Retail Pharmacies
        3. Others
      4. Brazil
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      5. Mexico
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      6. Argentina
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      7. Chile
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      8. Colombia
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
      9. Rest of LATAM
        1. Adalimumab
        2. Bevacizumab
        3. Infliximab
        4. Rituximab
        5. Trastuzumab
        6. Others
        7. Oncology
        8. Autoimmune diseases
        9. Others
        10. Hospital Pharmacies
        11. Drug Stores & Retail Pharmacies
        12. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.